CD274 and neoplasm: Of those, the most validated and clinically used biomarkers for ICI responses are three FDA-approved positive predictive biomarkers: programmed death-ligand 1 (PD-L1), microsatellite instability/defective mismatch repair (MSI/dMMR), and tumor mutational burden (TMB).